康尔诺 康尔诺
康尔诺 康尔诺
Home
About Us
Company Overview Core Team Corporate Culture Qualification Patent Branch Introduction
Products & Services
Product Introduction Research Project
News Center
Company News Industry Trends Technical Literature
Join Us
Talent Philosophy Staff Activities Job Openings
Cooperate
Clinical Research Partnership Opportunities Commissioned Treatment Contact Information
简体中文 English
Home

About Us

Company Overview Core Team Corporate Culture Qualification Patent Branch Introduction

Products & Services

Product Introduction Research Project

News Center

Company News Industry Trends Technical Literature

Join Us

Talent Philosophy Staff Activities Job Openings

Cooperate

Clinical Research Partnership Opportunities Commissioned Treatment Contact Information

Phase II Trial of Adjuvant Immunotherapy with Autologous Tumor-derived Gp96 Vaccination in Patients with ...

Source: Technical Literature2017-07-02

Previous

This is already the first article

Next

Heat shock protein peptide complex-96 vaccination for newly diagnosed glioblastoma: a phase I, single-arm trial

Related Information

Low MxA Expression Predicts Better Immunotherapeutic Outcomes in Glioblastoma Patients ...

2025-12-08

Chinese consensus on the diagnosis and treatment of gastric cancer with liver metastases

2025-12-08

Resection of Noncontrast-Enhancing Regions Deteriorated the Immunotherapeutic Efficacy of ...

2022-05-18

T cell receptor repertoire as a prognosis marker for heat shock protein peptide complex-96 vaccine...

2020-04-12

胃癌肝转移诊断与综合治疗中国专家共识(2019版)

2019-05-01

Consultation Hotline

0755-28893318

Address: 深圳市南山区粤海街道高新中一道十号深圳生物孵化基地2#407室

Scan the QR code
Follow the official official account

About Us
Company Overview Core Team Corporate Culture Qualification Patent Branch Introduction
Products & Services
Product Introduction Research Project
News Center
Company News Industry Trends Technical Literature
Join Us
Talent Philosophy Staff Activities Job Openings
Cooperate
Clinical Research Partnership Opportunities Commissioned Treatment Contact Information

Copyright © 2025 深圳市康尔诺生物技术有限公司 粤ICP备09190331号-1

Powered by vancheer